Piao Guanying, Wu Jiarui
School of Life Sciences, University of Science and Technology of China, Hefei, China ; Key Laboratory of Systems Biology, SIBS-Novo Nordisk Translational Research Centre for PreDiabetes, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Arch Med Sci. 2014 Feb 24;10(1):19-24. doi: 10.5114/aoms.2014.40730. Epub 2014 Feb 23.
Here we aimed to study the effectiveness of dexmedetomidine as an anesthetic adjunct in surgery.
A systematic evaluation was performed on published clinical trials. Major databases such as Medline database were employed to search and identify relevant studies and then Rev.Man 5 was used for meta-analysis as well as forest plots. Mean difference (MD) was chosen as the effect size for measurement data, while odds ratio (OR) was calculated for enumeration data.
A total of 18 studies met the inclusion criteria. The postoperative heart rate and mean arterial pressure for the dexmedetomidine group were significantly lower than the control group (combined MDs were -14.12 and -9.96). The incidence rates of postoperative nausea and vomiting, chills, and shivering of the dexmedetomidine group were lower than the control group (pooled ORs were 0.41, 0.21 and 0.14, respectively). However, the occurrence rates of bradycardia and hypotension in the dexmedetomidine group were higher than the control group (pooled ORs were 5.14 and 3.00).
Dexmedetomidine can stabilize blood pressure and heart rate, and prevent postoperative adverse reactions. However, patients with original hypovolemia or heart block should be cautious. Besides, the quality of such studies should be improved in methodology to evaluate their efficacy and safety comprehensively.
我们旨在研究右美托咪定作为手术麻醉辅助药物的有效性。
对已发表的临床试验进行系统评价。利用Medline数据库等主要数据库检索并识别相关研究,然后使用Rev.Man 5进行荟萃分析和绘制森林图。测量数据选用平均差(MD)作为效应量,计数数据计算比值比(OR)。
共有18项研究符合纳入标准。右美托咪定组术后心率和平均动脉压显著低于对照组(合并MD分别为-14.12和-9.96)。右美托咪定组术后恶心呕吐、寒战和颤抖的发生率低于对照组(合并OR分别为0.41、0.21和0.14)。然而,右美托咪定组心动过缓和低血压的发生率高于对照组(合并OR分别为5.14和3.00)。
右美托咪定可稳定血压和心率,预防术后不良反应。然而,原有血容量不足或心脏传导阻滞的患者应谨慎使用。此外,此类研究的方法学质量应予以提高,以便全面评估其疗效和安全性。